N
FTH

Nuveen’s Faeth Therapeutics FTH Stock Holding History

Nuveen’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,623
Closed -$133K – 3460
2022
Q1 		$133K Buy
2,623
+46
+2% +$3.66K ﹤0.01% 3229
2021
Q4 		$271K Sell
2,577
-240
-9% -$35.9K ﹤0.01% 3193
2021
Q3 		$548K Buy
2,817
+2,190
+349% +$399K ﹤0.01% 3150
2021
Q2 		$122K Buy
627
+10
+2% +$2.47K ﹤0.01% 3266
2021
Q1 		$179K Buy
+617
New +$206K ﹤0.01% 3253

Other funds holding FTH

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen's FTH Position: Q2 2022 in Review

Nuveen sold out of Faeth Therapeutics (FTH) in Q2 2022, closing a stake of 2,623 shares — an estimated $133K sold.

Nuveen first reported a position in FTH in Q1 2021 and held it in 5 quarters. The position peaked at $548K in Q3 2021. 39 funds tracked by Wall St. Rank hold FTH as of Q2 2022.

  • Nuveen reported no remaining Faeth Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 2,623 Faeth Therapeutics shares in Q2 2022, an estimated $133K.
  • Nuveen first reported a position in Faeth Therapeutics in Q1 2021 and held it in 5 quarters.
  • Nuveen's Faeth Therapeutics position peaked at $548K in Q3 2021.
  • 39 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.